EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 Stud

TransCode Therapeutics announced successful completion of Phase 1a clinical trial for TTX-MC138, showing safety and disease stabilization in patients with advanced cancer.

Raccontata dabenzinga.com